Allergy Therapeutics is a long-established specialist in the prevention, diagnosis and treatment...
Featured articles
The study involving lenzilumab showed a reduction in cytokine release syndrome and...
The deal with the Department of Coffee & Social Affairs follows news yesterday that the...
The Maryland-based company is seeing steady revenue growth through an expansion of services,...
Sublocade is seen as a long-term replacement for Suboxone, which is losing market share to...
Patent expiries on key blockbusters such as Crestor and Seroquel have put a huge dent in sales...
Featured companies
Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural m...
Sativa seeks to invest in companies which are well-placed to take advantage of the dynamic reg...
We are an Oxford-based company with a unique and powerful computer-based drug discovery platfo...
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietar...
Motif Bio plc (AIM/NASDAQ: MTFB) is a clinical-stage biopharmaceutical company focused on deve...
Arix Bioscience is a global healthcare and life science company that drives value in private a...
Global biotech Newswire
Seneca Partners’ holding in the company increases to 20.9% from 14.6% after it bought stock at...
Lender Hercules Capital will receive an immediate US$7mln
Allergy Therapeutics is a long-established specialist in the prevention, diagnosis and treatment...
The study involving lenzilumab showed a reduction in cytokine release syndrome and...
The firm said that it had concluded following the review that a revised strategy was required to...
The deal with the Department of Coffee & Social Affairs follows news yesterday that the...
The Maryland-based company is seeing steady revenue growth through an expansion of services,...
The office will take advantage of the Cambridge area's focus on biotech
The $4.5 million investment is in the form of a convertible security with a maturity date of 24...
Executive video interviews
Dr Cath O'Neill, CEO of SkinBioTherapeutics PLC (LON:SBTX), says her successor...
AdAlta Ltd (ASX: 1AD) CEO Sam Cobb speaks to Proactive Investors about the biotech's...
Anima Biotech CEO Yochi Slonim sat down with Proactive Investors at the BIO CEO &...
CEL-SCI Corporation (NYSE American: CVM) CEO Geert Kersten spoke with Proactive...
Illustratum Limited CEO David Trevor spoke to Proactive Investors at the BIO CEO and...
Propanc Biopharma, Inc. (OTCQB: PPCB) CEO James Nathanielsz sat down with Proactive...
Paion AG (OTCMKTS:PAIOF) CEO Wolfgang Soehngen sat down with Proactive Investors at the...
Onconova Therapeutics, Inc. (NASDAQ:ONTX) President & CEO Steven Fruchtman spoke...
Dyadic International Inc (OTCQX: DYAI) Chief Commercial Officer Matthew Jones sat down...
Agile Therapeutics Inc (NASDAQ:AGRX) CEO Al Altomari sat down with Proactive Investors...
AXIM Biotechnologies Inc (OTCQB: AXIM) CEO John Huemoeller tells Proactive Investors...
Landos Biopharma Inc CEO Josep Bassaganya-Riera sat down with Proactive Investors at the...
Big picture investment ideas in Biotech Capital
Allergy Therapeutics is a long-established specialist in the prevention, diagnosis and treatment...
The company’s B-cell peptide cancer vaccines have shown promise in pre-clinical and early-stage...
The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and...
The company’s digital platform and Artificial Intelligence (AI) software manages and helps...
“If successful, this platform [AP103] has potential in other genetic skin conditions and beyond”
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead...
The cancer detection device is on track to finish a key clinical study in the first quarter of...
CEO Gary Phillips says Pharmaxis’ healthy cash balance gives it time to choose between in-house...
Leronlimab shows promise as an antiviral agent with fewer side effects, lower toxicity and less...
Capital Network Research
Shield Therapeutics PLC - Feraccru: a potential game changer in the...
January 18 2019
Feraccru is a unique, non-salt, formulation oral iron: strong...
Avacta Group - Maximising Affimer's potential across therapeutics and...
October 03 2018
Over the last year or so, management has delivered significant progress in bringing their...
Judges Scientific PLC - 2018 Interim Results
September 21 2018
Judges Scientific reported results for the first half of 2018. The period included a...
Legendary Investments - Hidden value potential
September 03 2018
Legendary Investments (LON:LEG) creates value through privately held and pre-market...
Avacta Group - Exciting partnership with Bach BioSciences
July 30 2018
Avacta Group Plc (LON:AVACT) has recently finalised a co-development partnership with...
Avacta Group - Rapid Progress of Immuno-oncology Programs
April 16 2018
KEY INVESTOR MESSAGES
Faster than expected development of the second immuno-oncology...
Partners:
